@article{vera_seom_2016,
	title = {{SEOM} {Clinical} {Guideline} for the treatment of pancreatic cancer (2016)},
	volume = {18},
	issn = {1699-048X, 1699-3055},
	url = {https://link.springer.com/article/10.1007/s12094-016-1586-x},
	doi = {10.1007/s12094-016-1586-x},
	abstract = {Pancreatic cancer remains an aggressive disease with a 5 year survival rate of 5\%. Only 15\% of patients with pancreatic cancer are eligible for radical surgery. Evidence suggests a benefit on survival with adjuvant chemotherapy (gemcitabine o fluourouracil) after R1/R0 resection. Adjuvant chemoradiotherapy is also a valid option in patients with positive margins. Borderline resectable pancreatic cancer is defined as the involvement of the mesenteric vasculature with a limited extension. These tumors are technically resectable, but with a high risk of positive margins. Neoadjuvant treatment represents the best option for achieving an R0 resection. In advanced disease, two new chemotherapy treatment schemes (Folfirinox or Gemcitabine plus nab-paclitaxel) have showed improvements in overall survival compared with gemcitabine alone. Progress in pancreatic cancer treatment will require a better knowledge of the molecular biology of this disease, focusing on personalized cancer therapies in the near future.},
	language = {en},
	number = {12},
	urldate = {2017-02-24},
	journal = {Clinical \& Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico},
	author = {Vera, R. and Dotor, E. and Feliu, J. and González, E. and Laquente, B. and Macarulla, T. and Martínez, E. and Maurel, J. and Salgado, M. and Manzano, J. L.},
	year = {2016},
	pages = {1172--1178},
}

{"_id":"reDfLEPnLPrtAnozv","bibbaseid":"vera-dotor-feliu-gonzlez-laquente-macarulla-martnez-maurel-etal-seomclinicalguidelineforthetreatmentofpancreaticcancer2016-2016","downloads":0,"creationDate":"2018-10-11T03:50:30.924Z","title":"SEOM Clinical Guideline for the treatment of pancreatic cancer (2016)","author_short":["Vera, R.","Dotor, E.","Feliu, J.","González, E.","Laquente, B.","Macarulla, T.","Martínez, E.","Maurel, J.","Salgado, M.","Manzano, J. L."],"year":2016,"bibtype":"article","biburl":"https://bibbase.org/zotero/Bibliotecacst","bibdata":{"bibtype":"article","type":"article","title":"SEOM Clinical Guideline for the treatment of pancreatic cancer (2016)","volume":"18","issn":"1699-048X, 1699-3055","url":"https://link.springer.com/article/10.1007/s12094-016-1586-x","doi":"10.1007/s12094-016-1586-x","abstract":"Pancreatic cancer remains an aggressive disease with a 5 year survival rate of 5%. Only 15% of patients with pancreatic cancer are eligible for radical surgery. Evidence suggests a benefit on survival with adjuvant chemotherapy (gemcitabine o fluourouracil) after R1/R0 resection. Adjuvant chemoradiotherapy is also a valid option in patients with positive margins. Borderline resectable pancreatic cancer is defined as the involvement of the mesenteric vasculature with a limited extension. These tumors are technically resectable, but with a high risk of positive margins. Neoadjuvant treatment represents the best option for achieving an R0 resection. In advanced disease, two new chemotherapy treatment schemes (Folfirinox or Gemcitabine plus nab-paclitaxel) have showed improvements in overall survival compared with gemcitabine alone. Progress in pancreatic cancer treatment will require a better knowledge of the molecular biology of this disease, focusing on personalized cancer therapies in the near future.","language":"en","number":"12","urldate":"2017-02-24","journal":"Clinical & Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico","author":[{"propositions":[],"lastnames":["Vera"],"firstnames":["R."],"suffixes":[]},{"propositions":[],"lastnames":["Dotor"],"firstnames":["E."],"suffixes":[]},{"propositions":[],"lastnames":["Feliu"],"firstnames":["J."],"suffixes":[]},{"propositions":[],"lastnames":["González"],"firstnames":["E."],"suffixes":[]},{"propositions":[],"lastnames":["Laquente"],"firstnames":["B."],"suffixes":[]},{"propositions":[],"lastnames":["Macarulla"],"firstnames":["T."],"suffixes":[]},{"propositions":[],"lastnames":["Martínez"],"firstnames":["E."],"suffixes":[]},{"propositions":[],"lastnames":["Maurel"],"firstnames":["J."],"suffixes":[]},{"propositions":[],"lastnames":["Salgado"],"firstnames":["M."],"suffixes":[]},{"propositions":[],"lastnames":["Manzano"],"firstnames":["J.","L."],"suffixes":[]}],"year":"2016","pages":"1172–1178","bibtex":"@article{vera_seom_2016,\n\ttitle = {{SEOM} {Clinical} {Guideline} for the treatment of pancreatic cancer (2016)},\n\tvolume = {18},\n\tissn = {1699-048X, 1699-3055},\n\turl = {https://link.springer.com/article/10.1007/s12094-016-1586-x},\n\tdoi = {10.1007/s12094-016-1586-x},\n\tabstract = {Pancreatic cancer remains an aggressive disease with a 5 year survival rate of 5\\%. Only 15\\% of patients with pancreatic cancer are eligible for radical surgery. Evidence suggests a benefit on survival with adjuvant chemotherapy (gemcitabine o fluourouracil) after R1/R0 resection. Adjuvant chemoradiotherapy is also a valid option in patients with positive margins. Borderline resectable pancreatic cancer is defined as the involvement of the mesenteric vasculature with a limited extension. These tumors are technically resectable, but with a high risk of positive margins. Neoadjuvant treatment represents the best option for achieving an R0 resection. In advanced disease, two new chemotherapy treatment schemes (Folfirinox or Gemcitabine plus nab-paclitaxel) have showed improvements in overall survival compared with gemcitabine alone. Progress in pancreatic cancer treatment will require a better knowledge of the molecular biology of this disease, focusing on personalized cancer therapies in the near future.},\n\tlanguage = {en},\n\tnumber = {12},\n\turldate = {2017-02-24},\n\tjournal = {Clinical \\& Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico},\n\tauthor = {Vera, R. and Dotor, E. and Feliu, J. and González, E. and Laquente, B. and Macarulla, T. and Martínez, E. and Maurel, J. and Salgado, M. and Manzano, J. L.},\n\tyear = {2016},\n\tpages = {1172--1178},\n}\n\n","author_short":["Vera, R.","Dotor, E.","Feliu, J.","González, E.","Laquente, B.","Macarulla, T.","Martínez, E.","Maurel, J.","Salgado, M.","Manzano, J. L."],"key":"vera_seom_2016","id":"vera_seom_2016","bibbaseid":"vera-dotor-feliu-gonzlez-laquente-macarulla-martnez-maurel-etal-seomclinicalguidelineforthetreatmentofpancreaticcancer2016-2016","role":"author","urls":{"Paper":"https://link.springer.com/article/10.1007/s12094-016-1586-x"},"downloads":0,"html":"","metadata":{"authorlinks":{}}},"search_terms":["seom","clinical","guideline","treatment","pancreatic","cancer","2016","vera","dotor","feliu","gonzález","laquente","macarulla","martínez","maurel","salgado","manzano"],"keywords":[],"authorIDs":[],"dataSources":["TR9pX4mH5rDPr29Zo"]}